Lates News

On March 19, AstraZeneca announced plans to establish a commercial production and innovation center for cell therapy in Shanghai. On the same day, the company signed a memorandum of understanding for multi-party cooperation with the Shanghai Science and Technology Committee and leading research and financial institutions in the UK. AstraZeneca will build a dedicated commercial production and supply base for cell therapy in the Lingang New Area of the Shanghai Free Trade Zone for the commercial production and supply of autologous CAR-T cell therapy in China and other Asian markets. This includes AZD0120, a BCMA/CD19 dual-target CAR-T cell therapy developed based on the FasTCAR rapid production platform from Genwell Bio. (Jiemian)